Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 1 of 5
`Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 1of5
`
`
`
`
`
`
`
`
`
`
`EXHIBIT E
`EXHIBIT E
`
`

`

`Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 2 of 5
`
`Myeloid Therapeutics Enters Into
`Agreement with Acuitas
`Therapeutics for Lipid Nanoparticle
`(LNP) System, Enabling the First-
`Ever Delivery of mRNA-Encoded
`CARs Directly to Humans
`
`NEWS PROVIDED BY
`Myeloid Therapeutics
`
`May 19, 2022, 08:00 ET
`
`- Myeloid's monocyte-specific CAR technology combined with Acuitas' industry-leading LNP
`portfolio will accelerate in vivo cell programming for cancer patients -  
`
`- This strategic step complements Myeloid's existing pipeline and illustrates its continued
`leadership position across multiple myeloid-targeting modalities, including cell therapy and
`in vivo programming -
`
`- Acuitas' agreement enables Myeloid to progress up to 6 target programs -
`
`CAMBRIDGE, Mass., May 19, 2022 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid" or the
`"Company"), a clinical stage mRNA-immunotherapy company developing novel therapies for
`cancer and autoimmune diseases, today announced that it has entered into an agreement
`
`
`
`https://www.prnewswire.com/news-releases/myeloid-therapeutics-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-lnp-system-enabling-the-first-ever-delivery-of-mrna-encoded-cars-directly-to-humans-301551149.html
`Printed October 2, 2022
`
`

`

`with Acuitas Therapeutics ("Acuitas"), a global leader in developing LNP delivery systems that
`Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 3 of 5
`enable mRNA-based therapeutics. 
`
`The companies will combine the power of Acuitas' LNP technology with Myeloid's in vivo
`mRNA cell programming technology to develop next-generation immunotherapies for
`cancer.  The initial in vivo programming technologies are based on Myeloid's proprietary
`CARs, that are designed to be specifically expressed by myeloid and other immune
`cells.  Through this agreement, Myeloid de-risks the development of its candidates by
`leveraging Acuitas' science and proven regulatory, manufacturing and scale-up experience,
`to rapidly translate Myeloid's innovation to patients.
`
`"We are thrilled to announce our agreement with Acuitas, whose proven LNP technology is
`safe and effective and used in commercially-approved products such as COMIRNATY®," said
`Daniel Getts, Ph.D., CEO of Myeloid.  "We look forward to harnessing Acuitas' technology to
`unlock the power of our in vivo programming approach, which has demonstrated the ability
`to remodel the tumor microenvironment and have potent anti-tumor activity in preclinical
`models.  The combined science and commercial experience, coupled with our shared
`mindset of innovation, reflects a great strategic fit for Myeloid."
`
`"Myeloid's in vivo programming technology represents an important advancement in drug
`development and Acuitas is proud to be working with the Myeloid team. There is a
`continuing need for better cancer therapies and such LNP-CAR products may offer improved
`clinical outcomes," said Dr. Thomas Madden, President & CEO of Acuitas Therapeutics.
`
`About Myeloid's in vivo Programming Platform
`
`Myeloid's novel in vivo engineering platform specifically targets and activates myeloid cells to
`elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates
`that delivery of LNPs encapsulating mRNA results in selective uptake and expression by
`myeloid cells in vivo, leading to potent tumor killing in multiple cold tumor models. At AACR
`2022, Myeloid presented late-breaking data demonstrating the potential of Myeloid's
`technology to program cells directly in vivo.  Myeloid is currently advancing two in vivo
`
`
`
`https://www.prnewswire.com/news-releases/myeloid-therapeutics-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-lnp-system-enabling-the-first-ever-delivery-of-mrna-encoded-cars-directly-to-humans-301551149.html
`Printed October 2, 2022
`
`

`

`programming programs, MT-301 and MT-302, through IND-enabling studies against validated
`Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 4 of 5
`cancer targets in attractive therapeutic markets.   The MT-301 and MT-302 programs will
`utilize Acuitas' LNP deliver technology. 
`
`About Acuitas Therapeutics 
`
`Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a
`private biotechnology company that specializes in the development of delivery systems for
`nucleic acid therapeutics based on lipid nanoparticles. The company partners with
`pharmaceutical and biotechnology companies and academic institutes to advance nucleic
`acid therapeutics into clinical trials and to the marketplace. The team works with partners to
`develop new therapies to address unmet clinical needs based on its internationally
`recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place
`with several partners to use its proprietary lipid nanotechnology in the development of
`COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY®, which has received full
`approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and
`many other countries.
`
`About Myeloid Therapeutics
`
`Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel
`therapies for cancer and autoimmune diseases. Integrating the fields of RNA, immunology
`and medicine, the Company's proprietary platform provides clinical solutions by matching
`therapeutic modalities to disease conditions, including use of  autologous cell therapies, in
`vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-
`targeted biologics.  For more information, visit https://www.myeloidtx.com/.
`
`Investor Contact
`Amy Conrad
`Juniper Point
`Amy@juniper-point.com
`858-914-1962
`
`SOURCE Myeloid Therapeutics
`
`
`
`https://www.prnewswire.com/news-releases/myeloid-therapeutics-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-lnp-system-enabling-the-first-ever-delivery-of-mrna-encoded-cars-directly-to-humans-301551149.html
`Printed October 2, 2022
`
`

`

`Case 1:22-cv-02229-MKV Document 45-5 Filed 10/04/22 Page 5 of 5
`
`
`
`https://www.prnewswire.com/news-releases/myeloid-therapeutics-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-lnp-system-enabling-the-first-ever-delivery-of-mrna-encoded-cars-directly-to-humans-301551149.html
`Printed October 2, 2022
`
`